Eisai (OTCMKTS:ESALY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The brokerage currently has a $79.00 price target on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 7.67% from the stock’s current price.
According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “
Separately, ValuEngine raised Eisai from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th.
Eisai opened at $73.37 on Friday, Marketbeat.com reports. Eisai has a fifty-two week low of $49.86 and a fifty-two week high of $73.37. The company has a quick ratio of 1.82, a current ratio of 2.15 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $20.98 billion, a PE ratio of 57.77 and a beta of -0.33.
Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. It offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer's disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment.
Get a free copy of the Zacks research report on Eisai (ESALY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.